Jennifer Curtis, Nan Wang and Cody Powers discuss how to drive stronger global strategy, focusing on the trends in early and late-stage pharma acquisitions.


Key takeaways:

  • Innovation is far more diffuse today, reflecting the increasingly fragmented nature of the pharma industry.
  • Late-stage deals significantly underperformed compared to composite early-stage strategy, with the difference in some cases rising two- or three-fold.
  • Ideas and opportunities may exist in scaling up early-stage opportunities or embracing large-cap collaborations and potential venture roles.